Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28597
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNeto, Ary Serpa-
dc.contributor.authorLandoni, Giovanni-
dc.contributor.authorOstermann, Marlies-
dc.contributor.authorLumlertgul, Nuttha-
dc.contributor.authorForni, Lui-
dc.contributor.authorAlvarez-Belon, Lucas-
dc.contributor.authorTrapani, Tony-
dc.contributor.authorAlliegro, Patricia V-
dc.contributor.authorZacharowski, Kai-
dc.contributor.authorWiedenbeck, Carolin-
dc.contributor.authorde Backer, Daniel-
dc.contributor.authorBellomo, Rinaldo-
dc.date2022-01-21-
dc.date.accessioned2022-01-18T04:46:14Z-
dc.date.available2022-01-18T04:46:14Z-
dc.date.issued2022-05-
dc.identifier.citationJournal of Medical Virology 2022; 94(5): 2079-2088en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/28597-
dc.description.abstractIn order to expand our understanding of the role of angiotensin II (ANGII) in COVID-19, we conducted an international, multicenter registry study to assess the use of ANGII in patients with COVID-19 compared to patients not receiving ANGII. Critically ill adult patients who were diagnosed with COVID-19 and received ANGII were matched with COVID-19 patients not receiving ANGII according to age, respiratory support, history of hypertension, use of angiotensin converting enzyme inhibitors and/or angiotensin II receptor blocker, and date of admission. All outcomes were exploratory in nature and included improvement in oxygenation, duration of organ support and mortality. In one year, 132 patients were included (65 in ANGII group and 67 in the control group), and patients were comparable in baseline characteristics. During the first 12 hours of infusion, patients in the ANGII had a faster decrease in FiO2 and maintained similar mean arterial pressure levels. Hospital mortality was not statistically significantly different between the groups (53.8% vs. 40.3%; p = 0.226). Within the limitations of such a study design, our findings confirm previous observations of a potentially positive effect of ANGII on blood pressure and FiO2 but no effect on patient-centered outcomes. This article is protected by copyright. All rights reserved.en
dc.language.isoeng
dc.subjectBiochemical analysisen
dc.subjectCoronavirusen
dc.subjectPathogenesisen
dc.subjectResearch and Analysis Methodsen
dc.subjectRespiratory tracten
dc.subjectSARS coronavirusen
dc.subjectVirus classificationen
dc.titleAngiotensin II Infusion in COVID-19: An International, Multicenter, Registry-based Study.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Medical Virologyen
dc.identifier.affiliationIntensive Care.en
dc.identifier.affiliationData Analytics Research and Evaluation (DARE) Centre..en
dc.identifier.affiliationDepartment of Critical Care, University of Melbourne, Melbourne, Australia..en
dc.identifier.affiliationAustralian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia..en
dc.identifier.affiliationDepartment of Critical Care Medicine, Hospital Israelita Albert Einstein, Sao Paulo, Brazil..en
dc.identifier.affiliationDepartment of Intensive Care and Anesthesiology, IRCCS San Raffaele Scientific Institute, Milan, Italy..en
dc.identifier.affiliationVita-Salute San Raffaele University, Milan, Italy..en
dc.identifier.affiliationDepartment of Intensive Care, Royal Melbourne Hospital, Melbourne, Australia..en
dc.identifier.affiliationDepartment of Critical Care, Guys & St Thomas' Foundation Trust, London, United Kingdom..en
dc.identifier.affiliationDepartment of Intensive Care, Royal Surrey County Hospital NHS Foundation Trust, Surrey, United Kingdom..en
dc.identifier.affiliationDepartment of Anesthesiology, Intensive Care Medicine & Pain Therapy, University Hospital Frankfurt, Goethe University, Frankfurt, Germany..en
dc.identifier.affiliationIntensive Care Departments, CHIREC Hospitals, Brussels and Braine l'Alleaud-Waterloo, Belgium..en
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35029318/en
dc.identifier.doi10.1002/jmv.27592en
dc.type.contentTexten
dc.identifier.orcid0000-0003-1520-9387en
dc.identifier.orcid0000-0002-1650-8939en
dc.identifier.pubmedid35029318
local.name.researcherBellomo, Rinaldo
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptIntensive Care-
crisitem.author.deptData Analytics Research and Evaluation (DARE) Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

34
checked on Nov 1, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.